Guardant Reveal™, is a plasma-only circulating tumor DNA (ctDNA) test that will be indicated for detection of early-stage colorectal cancer, with additional cancer types to follow . . .
Home Translational Medicine Biomarkers Guardant Health Launches Early-Stage Colorectal Cancer ctDNA Assay

- Translational Medicine
- Biomarkers
- Cancer
- Colorectal Cancer
- GEN Edge
- Liquid Biopsies
- Molecular Diagnostics/In vitro Diagnostics
Guardant Health Launches Early-Stage Colorectal Cancer ctDNA Assay
Bay Area liquid biopsy developer also plans expansion into tissue testing
Guardant Health says it plans to launch Guardant Reveal, its first blood-based liquid biopsy for residual disease detection and recurrence monitoring next month [Guardant Health]